Formulary E-News: Having trouble viewing this e-mail? Click here.  
Formulary E-News
January 07, 2011
Formulary
In this issue
�
 Daily aspirin linked to cancer mortality
�
 Safety labels for new cancer drugs
�
 Statin-fibrate concurrent therapy
�
 Three-drug regimen for myeloma
�
 Physicians accept dabigatran etexilate
 

Survey

This month we would like to know...

Egrifta (tesamorelin) was recently FDA-approved to treat HIV-associated lipodystrophy (aka, visceral adipose tissue [VAT]), which will be available this month. VAT has been associated with adverse cardiovascular outcomes. How is your health-system covering or planning on covering this injectable drug product?

1) We will be/are covering it as a medically necessary drug if patient's meet criteria for use.
   
2) We will be/are covering it as a medically necessary drug for all HIV patients.
   
3) We will not be covering it at all since it is a cosmetic product.
   
4) We have not yet decided how to cover this product.
   

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

Formulary
 Digital Edition

Click here to view the current edition.

Click here to subscribe.
 
Daily aspirin tied to decreased risk of cancer mortality
Daily aspirin taken for at least 5 years appears to greatly reduce mortality from gastrointestinal and non-gastrointestinal cancers, according to research published online in The Lancet, HealthDay News reported. More...
Many new cancer drugs require updated safety labels
Many serious or potentially fatal adverse reactions associated with new, targeted anticancer agents are not reported in the original published research on the drug, and they are not known to oncologists until years later when updated drug labels, including boxed warnings, are required, according to research published online in the Journal of Clinical Oncology, HealthDay News reported. More...
Combining statins and fibrates increases rhabdomyolysis risk
Patients who are newly treated with statin-fibrate concurrent therapy are slightly more likely to be hospitalized with rhabdomyolysis than those who take just one of the medications, according to research published in the American Journal of Cardiology, HealthDay News reported. More...
New 3-drug regimen improves outcomes for myeloma patients
The addition of bortezomib to the standard induction therapy before double autologous stem cell transplantation for patients with multiple myeloma appears to improve nearly threefold the rates of complete or near complete response, according to research published online in The Lancet, HealthDay News reported. More...
Physicians welcome dabigatran etexilate as alternative to warfarin
In a guest editorial, 2 researchers highlighted the importance of the FDA approval in October of dabigatran etexilate (Pradaxa, Boehringer Ingelheim), an oral thrombin inhibitor that provides an alternative to warfarin (Coumadin, Bristol-Myers Squibb) for long-term stroke prevention in patients with non-valvular atrial fibrillation. More...

Top 5 Web Stories:

 1. Focus on 2010: A year of novel pharmacologic agents in review

2. Focus on Azilsartan: A next-generation angiotensin II receptor blocker for the treatment of hypertension

3. Dabigatran etexilate (Pradaxa): An oral direct thrombin inhibitor

4. First-time generic approvals December 2010

5. Study finds acetaminophen increases blood pressure in patients with coronary artery disease

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.